More than 50,000 people die from colorectal cancer every year in the US alone. EV Therapeutics is a preclinical stage biotech company developing a novel colorectal cancer (CRC) therapeutic that reactivates the body's anti-tumor immune response in late-stage cancer patients. Colon cancer tumor cells are particularly good at shutting down the body's immune system to enable their survival. One important way this is done is through secretion of negative signals packaged in small vesicles (EVs) from the tumor cells that are received by the body's T-cells (the tumor killing cells). Our technology reengineers tumor EVs with competitive signals that allow the T-cells to activate, detect and kill the tumor cells. This approach enables 85% of CRC patients to restart their body's attack against the tumors when they otherwise were unable to do so. The founding team is led by world experts in colorectal cancer biology, EV based therapeutics CMC and manufacturing development, and clinical diagnostics. Our initial data in preclinical studies using both animal and human cell models demonstrate significant shrinkage in tumor size validating our novel approach. The team is seeking 3.5 million dollars to enable investigational new drug FDA filing milestones by the Q1 of 2025. The projected market size by 2026 for CRC related cancers is 24.5B dollars.
Ready to Ask For Funding for your company?
Post a Funding Request